Vaginal misoprostol vs. concentrated oxytocin plus low-dose prostaglandin E2 for second trimester pregnancy termination
✍ Scribed by John Owen; John C. Hauth
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 46 KB
- Volume
- 8
- Category
- Article
- ISSN
- 1057-0802
No coin nor oath required. For personal study only.
✦ Synopsis
Objective:
To examine the efficacy of vaginal misoprostol for mid-trimester pregnancy termination.
Methods:
This randomized trial compared misoprostol, 200 microg per vaginum q 12 h to a protocol of concentrated oxytocin plus low-dose vaginal prostaglandin e2 suppositories (10 mg q 6 h). success was defined as an induction-to-delivery interval < or =24 h.
Results:
Interim analysis of the first 30 (15-misoprostol, 15-concentrated oxytocin) women demonstrated that the 2 groups were similar with regard to indication for delivery, gestational age, and demographic characteristics. misoprostol was associated with a lower success rate (67 vs. 87%, p = .2), a longer induction-delivery interval (22 h vs. 18 h, p = .09), a higher rate of retained placenta requiring curettage (27 vs. 13%, p = .65), and a higher live birth rate (50 vs. 0%, p = .006).
Conclusions:
Compared to a regimen of concentrated oxytocin plus low-dose prostaglandin e2, misoprostol administered as vaginal tablets in a dose of 200 microg q 12 h is not satisfactory for mid-trimester pregnancy termination in an unselected population.